LDP-02 Millennium

Current Opinion in Investigational Drugs

Volumn 2, Issue 4, 2001, Pages 502-504

  Marshall, J K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; MLN 02; PLACEBO; UNCLASSIFIED DRUG; INTEGRIN; INTEGRIN ALPHA4BETA7; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LDP-02;

CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; ENTERITIS; HEADACHE; HUMAN; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTEGRINS;

EID: 0035047362     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Role of α4-integrins in lymphocyte homing to mucosal tissues in vivo
2. LeukoSite gets $750,000 NIH grant
3. Drug development pipeline
4. Genentech's year-end results show growth plan on track: Earnings increase nine percent on revenues exceeding $1 billion
5. LeukoSite reports year-end 1997 financial results; Strategic alliances and financing accelerate drug development efforts
6. LeukoSite reports third quarter 1998 financial results
7. LeukoSite signs agreement to acquire CytoMed; Purchase expected to add $15 million in cash and two clinical compounds
8. LeukoSite research and drug discovery programs
9. Lehman Brothers: Healthcare Global: PharmaPipelines - Volume 1 of 2
10. Millennium's product plays
11. Millennium initiates phase II clinical trial of LDP-02 in Crohn's disease
12. An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis
13. Digestive Disease Week 2000 (Part III), San Diego, CA, USA
14. Millennium's LDP-02 demonstrates encouraging clinical trial results in ulcerative colitis - Phase I/II data presented at Digestive Disease Week conference
15. Millennium submits Investigational New Drug Application to FDA for LDP-02 in ulcerative colitis
16. An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis
17. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7
18. Critical role for β7 integrins in formation of the gut-associated lymphoid tissue
19. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1
20. Monoclonal antibodies specific for β7 integrin and mucosal addressin cell adhesion molecule-1 reduce inflammation in the colon of SCID mice reconstituted with CD45RB-high CD4+ T cells
21. Structural requirements for mucosal vascular addressin binding to its lymphocyte receptor α4β7
22. Structure-function analysis of the integrin β7 subunit: Identification of domains involved in adhesion to MAdCAM-1
23. The α4 integrin subunit Tyr187 has a key role in α4β7-dependent cell adhesion
24. Molecular mapping of functional antibody binding sites of α4 integrin
25. Identification of putative ligand-binding sites of the integrin α4 β1 (VLA-4, CD49d/CD29)
26. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: Dissection of the molecular mechanisms
27. Millennium initiates phase II clinical trials of LDP-02 in ulcerative colitis: Anti-inflammatory compound advances in clinic
28. Amelioration of murine experimental colitis by inhibition of mucosal addressin adhesion molecule